Citalopram updated on 07-01-2025

Limb reduction defects (LRD)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S6005
R15391		 Furu, 2015 Limb reduction 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.16 [0.52;2.60] 6/11,193   1,031/2,266,875 1,037 11,193
ref
S7351
R21509		 Wemakor, 2015 Limb reduction 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.53 [0.03;8.79] C 0/20   784/17,847 784 20
ref
S6161
R16204		 Louik, 2007 Limb-reduction defects 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 4.00 [0.50;33.90] 1/16   192/6,037 193 16
ref
Total 3 studies 1.28 [0.62;2.64] 2,014 11,229
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Furu, 2015Furu, 2015 1.16[0.52; 2.60]1,03711,19381%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Wemakor, 2015Wemakor, 2015 0.53[0.03; 8.79]784207%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Louik, 2007Louik, 2007 4.00[0.50; 33.90]1931612%ROB confusion: moderateROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (3 studies) I2 = 0% 1.28[0.62; 2.64]2,01411,2290.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.16[0.52; 2.59]1,03711,193 -NAFuru, 2015 1 case control studiescase control studies 1.82[0.26; 12.53]9773621%NAWemakor, 2015 Louik, 2007 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.28[0.62; 2.64]2,01411,2290%NAFuru, 2015 Wemakor, 2015 Louik, 2007 3 Tags Adjustment   - No  - No 0.53[0.03; 8.79]78420 -NAWemakor, 2015 1   - Yes  - Yes 1.44[0.57; 3.65]1,23011,20913%NAFuru, 2015 Louik, 2007 2 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.09[0.50; 2.37]1,82111,2130%NAFuru, 2015 Wemakor, 2015 2   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 4.00[0.49; 32.94]19316 -NALouik, 2007 1 All studiesAll studies 1.28[0.62; 2.64]2,01411,2290%NAFuru, 2015 Wemakor, 2015 Louik, 2007 30.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.28[0.62; 2.64]2,01411,2290%NAFuru, 2015 Wemakor, 2015 Louik, 2007 30.510.01.0